Revised: 1 May 2020

Medicines

Policy Statements

Date Policy
 1 May 2020 COVID-19 - Potential shortage of fentanyl injection – use of unapproved product
22 April 2020 COVID-19 – point of care test kits – restriction on importation, manufacture, supply and use
13 April 2020 COVID-19 – Visitors to New Zealand who need more of their regular prescribed medicine
6 April 2020 COVID-19: Pharmacy Licensing: Closure & Relocation
28 March 2020 COVID-19: Medicine repurposing to treat COVID-19 infections
26 March 2020 COVID-19 Alert Level 4 - Manufacturers and suppliers of medicines as essential services
23 March 2020 COVID-19: Important message for Medsafe customers
23 March 2020 Submitting applications electronically to Medsafe
11 June 2018 What to do in the case of a potential out of stock
21 June 2017 Change to Label Statement Database for OTC loratadine and desloratadine medicines
18 April 2017 Tips for changing to the new data sheet format
19 October 2016 Reminder to sponsors: Timeframes for provisional consent
20 July 2015 Changes to Priority Assessment Process
28 May 2014 Changes to the Definition of Medicines and Medical Devices Effective 1 July 2014
2 May 2014 Biosimilars
10 July 2013 Subdividing of Tablets
6 May 2013 Electronic Submissions
6 May 2013 Proprietary Ingredients
1 February 2013 Update to Therapeutic Product Database Reports
February 2013 Changing Registration Situation
January 2012 Acceptability of Claims for Pain Relief
1 March 2010 Priority and Abbreviated Assessments


For further information see the current guidelines on the regulation of therapeutic products in New Zealand

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /